This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
British American Tobacco (BTI) Crossed Above the 200-Day Moving Average: What That Means for Investors
by Zacks Equity Research
Good things could be on the horizon when a stock surpasses the 200-day simple moving average. How should investors react?
Zacks Value Investor Highlights: Hess Corporation, Cleveland-Cliffs, British American Tobacco, KraftHeinz and GATX
by Zacks Equity Research
Hess Corporation, Cleveland-Cliffs, British American Tobacco, KraftHeinz and GATX have been highlighted in this Value Investor article.
Diving Into Berkshire Hathaway's 1970s Investing Playbook
by Tracey Ryniec
What can we learn from what Warren Buffett was up to during the high inflation of the 1970s?
British American Tobacco (BTI) Just Overtook the 20-Day Moving Average
by Zacks Equity Research
Should investors be excited or worried when a stock crosses above the 20-day simple moving average?
Zacks Investment Ideas feature highlights: Philip Morris International Inc., Altria Group, Inc. and British American Tobacco p.l.c
by Zacks Equity Research
Philip Morris International Inc., Altria Group, Inc. and British American Tobacco p.l.c are highlighted in this Investment Ideas article.
3 Defensive Stocks Breaking Out to New 52-Week Highs
by Bryan Hayes
3 Defensive Stocks Breaking Out to New 52-Week Highs
Philip Morris' (PM) IQOS, Beyond Nicotine Growth Plans On-Track
by Zacks Equity Research
Philip Morris (PM) benefits from the growing market for IQOS devices globally. It is also focused on the expansion of Beyond Nicotine products to support inhaled therapeutics.
Focus on Low-Risk Offerings Drives Altria (MO), Pricing Aids
by Zacks Equity Research
Altria (MO) strives to expand IQOS and on! amid consumers' rising preference on low-risk tobacco alternatives. Moreover, strong pricing for tobacco products is driving revenues.
Altria (MO) to Divest Ste. Michelle Wine Estates Business
by Zacks Equity Research
Altria's (MO) subsidiary agrees to sell Ste. Michelle Wine Estates business. The move will boost shareholders' value, while aiding in smooth transition of adult smokers to a non-combustible future.
Philip Morris (PM) Up 10% in 3 Months, Gains on Pricing & RRPs
by Zacks Equity Research
Philip Morris (PM) is gaining from rising popularity of IQOS devices. Additionally, pricing power, especially for combustible products, is an upside.
Altria (MO) Gains on Low-Risk Tobacco Offerings, Strong Pricing
by Zacks Equity Research
Altria's (MO) low-risk and oral tobacco offerings are gaining popularity. Moreover, high pricing for tobacco products is an upside.
Philip Morris (PM) Benefits From IQOS Growth & Strong Pricing
by Zacks Equity Research
Philip Morris (PM) gains from growth in the RRPs category, backed by rising popularity of IQOS devices. Additionally, pricing power, especially for combustible products, is an upside.
Altria (MO) Sees Growth in Low-Risk Products, Pricing Aids
by Zacks Equity Research
Altria's (MO) low-risk tobacco offerings such as IQOS and on! are gaining popularity. Moreover, high pricing for tobacco products are an upside..
Altria (MO) Looks Steady on Low-Risk Products & Strong Pricing
by Zacks Equity Research
Altria (MO) gains from the popularity of low-risk tobacco alternatives such as IQOS. Moreover, strong pricing for tobacco products supports revenues.
Philip Morris (PM) Gains on RRPs Popularity & Pricing Power
by Zacks Equity Research
Philip Morris' (PM) IQOS devices are gaining traction among consumers. Moreover, pricing power, especially for combustible products, is an upside.
Altria (MO) Benefits From Low-Risk Products & Pricing Power
by Zacks Equity Research
Altria (MO) gains from expansion of IQOS and oral tobacco offerings such as on! Moreover, pricing power is aiding revenues.
Altria (MO) Poised on Solid Pricing, Growth in Low Risk Products
by Zacks Equity Research
Altria (MO) gains from rising popularity of IQOS and oral tobacco offerings. Moreover, pricing power is supporting revenue growth.
Phillip Morris (PM) Poised for Growth on RRPs & Strong Pricing
by Zacks Equity Research
Philip Morris' (PM) strong offerings in the reduced risk products space and solid pricing of combustible products are driving growth.
Altria (MO) Gains on Low Risk Tobacco Products & Strong Pricing
by Zacks Equity Research
Altria's (MO) efforts to boost oral tobacco offerings and expansion of IQOS across stores are yielding. Moreover, pricing power is aiding revenue growth.
Will RRPs Growth Keep Driving Philip Morris (PM) in 2021?
by Zacks Equity Research
Philip Morris (PM) is gaining from growing popularity of IQOS, which is boosting revenues in the RRPs category.
Altria (MO) Gains on Low-Risk Products Amid Soft Cigarette Sales
by Zacks Equity Research
Altria (MO) is gaining from the popularity of low-risk tobacco alternatives such as IQOS and on!, as well as prudent pricing strategies.
Philip Morris's (PM) IQOS 3 Receives FDA Authorization for Sale
by Zacks Equity Research
FDA approves the sale of Philip Morris's (PM) IQOS devices in the United States. The latest device includes a number of technological advancements compared with its predecessors.
Should Value Investors Choose British American (BTI) Stock?
by Zacks Equity Research
Is British American Tobacco (BTI) a great pick from the value investor's perspective right now? Read on to know more.
Oral Tobacco Unit Supports Altria Amid Poor Cigarette Sales
by Zacks Equity Research
Altria (MO) is gaining from rising popularity of low risk tobacco alternatives. However the company's smokeable unit is bearing the brunt of soft cigarette sales.
RRPs a Respite for Philip Morris Amid Low Cigarette Sales
by Zacks Equity Research
Philip Morris (PM) is gaining from growing popularity of IQOS. However, low cigarette sales is a dampener.